Is it possible to compare exome data generated on an Ion Proton with exome data generated on an Illumina platform? I have sequenced germline samples on the proton and have sequenced tumour samples using Illumina and I am wondering if it will be at all possible to compare?
-
-
It's certainly possible to generate useful data in this case, but there will be a lot more noise than if everything was the same platform. The biggest issue will probably be not the difference in platforms, but the difference in baits/kits; if the tumor sample has 0 coverage for some gene that has 50x coverage in the control, you won't really know if that's because the gene got deleted, or because the capture was ineffective in that area.
I suggest you calculate the cost of person-hours spent analyzing this data versus the cost of rerunning on or the other so that all data is from the same platform. It does not make sense to spend $50k chasing down and validating spurious differences that could be wiped out en masse with $1k of sequencing. The alternate platform's data is not wasted in this case, either, as it can increase confidence in variations found (or not found) in the other platform. -
Yes, that is what I am wondering - would it be much better to sequence both on the same platform?Comment
-
Hi rjones89. You could compare the data from 2 platforms, but for the INDELS. The SNP variants called could be compared. Let me know if you need help with this, if you are interested in analysis of only the SNP variants.
We (Genotypic Technology - www.genotypic.co.in) are a Genomics services provider based in India. Write to me at [email protected] with your query and we can discuss more on this. I will work out the best possible price for analysis work.
Thanks.Comment
-
Ion Torrent just released the HiQ chemistry for the Ion Torrent. They claim that the indel problem has been resolved.Comment
-
-
Hey there...we keep commercial activities in the Vendor Forum and discourage overt commercial posting...please contact me if you want permission to post in the Vendor Forum. Thanks.
Originally posted by kushald View PostComment
-
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...07-31-2026, 11:01 AM -
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM
Comment